dfcomb: An R-package for phase I/II trials of drug combinations

被引：2

作者：

Riviere, Marie-Karelle ^{[1
]}

Jourdan, Jacques-Henri ^{[2
]}

Zohar, Sarah ^{[1
]}

机构：

[1] Univ Paris 06, INSERM, U1138, Univ Paris 05,Equipe 22,Ctr Rech Cordeliers, Paris, France

[2] INRIA Paris Rocquencourt, Paris, France

来源：

COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE | 2016年 / 125卷

关键词：

Dose-finding; Phase I; Combination; Adaptive design; R package; DOSE-FINDING DESIGN; AGENT;

D O I：

10.1016/j.cmpb.2015.10.018

中图分类号：

TP39 [计算机的应用];

学科分类号：

081203 ; 0835 ;

摘要：

In this paper, we present the dfcomb R package for the implementation of a single prospective clinical trial or simulation studies of phase I combination trials in oncology. The aim is to present the features of the package and to illustrate how to use it in practice though different examples. The use of combination clinical trials is growing, but the implementation of existing model-based methods is complex, so this package should promote the use of innovative adaptive designs for early phases combination trials. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：117 / 133

页数：17

共 14 条

[1] Perspectives on the development of a molecularly targeted agent [J].

Druker, BJ .

CANCER CELL, 2002, 1 (01) :31-36

[2] Antiangiogenic therapy: More promise and, yet again, more questions [J].

Ellis, LM .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3897-3899

[3]

Faries D, 1994, J Biopharm Stat, V4, P147, DOI 10.1080/10543409408835079

[4] High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients-Systematic review and meta-analysis [J].

Gafter-Gvili, Anat ;

Leader, Avi ;

Gurion, Ronit ;

Vidal, Liat ;

Ram, Ron ;

Shacham-Abulafia, Adi ;

Ben-Bassat, Isaac ;

Lishner, Michael ;

Shpilberg, Ofer ;

Raanani, Pia .

AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (08) :657-662

[5] A COMPARISON OF 2 PHASE-I TRIAL DESIGNS [J].

KORN, EL ;

MIDTHUNE, D ;

CHEN, TT ;

RUBINSTEIN, LV ;

CHRISTIAN, MC ;

SIMON, RM .

STATISTICS IN MEDICINE, 1994, 13 (18) :1799-1806

[6] A product of independent beta probabilities dose escalation design for dual-agent phase I trials [J].

Mander, Adrian P. ;

Sweeting, Michael J. .

STATISTICS IN MEDICINE, 2015, 34 (08) :1261-1276

[7] Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases:: Results from two phase I studies [J].

Morgan, B ;

Thomas, AL ;

Drevs, J ;

Hennig, J ;

Buchert, M ;

Jivan, A ;

Horsfield, MA ;

Mross, K ;

Ball, HA ;

Lee, L ;

Mietlowski, W ;

Fuxius, S ;

Unger, C ;

O'Byrne, K ;

Henry, A ;

Cherryman, GR ;

Laurent, D ;

Dugan, M ;

Marmé, D ;

Steward, WP .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3955-3964

[8] Experimental designs for phase I and phase I/II dose-finding studies [J].

O'Quigley, J ;

Zohar, S .

BRITISH JOURNAL OF CANCER, 2006, 94 (05) :609-613

[9]

Pournelle G. H., 1953, Journal of Mammalogy, V34, P133, DOI 10.1890/0012-9658(2002)083[1421:SDEOLC]2.0.CO

[10]

← 1 2 →